What Is Lymphosarcoma Cancer? Signs, Diagnosis, and Treatment

Lymphosarcoma is a cancer of lymphocytes, the white blood cells that form the backbone of the immune system. The term is largely synonymous with what most modern oncologists call lymphoma, though “lymphosarcoma” persists in veterinary medicine and older medical literature. It can arise in virtually any organ or tissue where lymphocytes reside, which means it shows up in lymph nodes, the spleen, liver, bone marrow, gut, skin, and sometimes less expected places like the eyes or nervous system. The disease affects dogs, cats, cattle, and humans, and while the details differ across species, the underlying biology is strikingly similar.

Why the Name “Lymphosarcoma” Still Appears

In human medicine, the World Health Organization’s classification system dropped “lymphosarcoma” decades ago in favor of more precise labels that distinguish dozens of lymphoma subtypes. In veterinary medicine, the older term hung on much longer and still shows up in textbooks, diagnostic reports, and conversations between veterinarians and pet owners. If your vet says lymphosarcoma, they almost always mean the same disease a human oncologist would call non-Hodgkin lymphoma. Both B lymphocytes and T lymphocytes can give rise to it. These cells are uniquely vulnerable to becoming cancerous because of the way they do their normal jobs: they repeatedly rearrange their own DNA to build receptors that recognize infections, they can multiply explosively when they encounter a threat, and they can survive for years as memory cells. Each of those useful traits also creates opportunities for something to go wrong at the genetic level.

How It Presents in Dogs

Dogs are the species most frequently diagnosed with lymphosarcoma, and the multicentric form is by far the most common. That means it tends to involve many lymph nodes at once rather than staying localized. The classic sign is painless, firm swelling of the lymph nodes you can feel under the jaw, in front of the shoulders, behind the knees, and in the groin. Many owners first notice a lump while petting their dog and are surprised that the dog seems to feel fine otherwise.

That initial appearance of good health can be misleading. In a study of dogs with multicentric lymphoma, the most common presentation was generalized lymph node enlargement, but roughly a third also showed additional signs such as excessive thirst and urination, facial swelling, or upper airway obstruction. About two-thirds had blood abnormalities including low platelet counts, anemia, and abnormal white blood cell numbers. By the time of diagnosis, the vast majority of dogs were already at stage III or higher, meaning the disease was widespread.

Beyond the multicentric form, dogs can develop alimentary lymphoma (affecting the gut), mediastinal lymphoma (a mass in the chest), cutaneous lymphoma (on or in the skin), and extranodal lymphoma that targets a single organ like the kidney, eye, or central nervous system. Each form has its own set of warning signs. Alimentary lymphoma often causes vomiting, diarrhea, and weight loss. Mediastinal lymphoma can compress the airways or major blood vessels in the chest, causing coughing, labored breathing, or swelling of the head and forelimbs.

Lymphosarcoma in Cats

Cats develop lymphoma at a high rate as well, and the picture is shaped heavily by whether the cat carries certain viruses. Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are the two biggest known risk factors. A systematic review of Brazilian feline lymphoma cases found that the location of the cancer shifted dramatically depending on the cat’s viral status. FeLV-positive cats had about a ninefold higher risk of developing mediastinal lymphoma (the chest form), while FeLV-negative cats were far more likely to develop intestinal lymphoma, with roughly a twelvefold increase in gastrointestinal disease compared to FeLV-positive cats.

This viral connection matters practically. Widespread FeLV vaccination has reduced the rate of mediastinal and multicentric lymphoma in cats considerably over the past few decades, but gastrointestinal lymphoma in older, FeLV-negative cats has become more prominent as the population ages. Signs of intestinal lymphoma in cats tend to develop slowly: gradual weight loss, intermittent vomiting, poor appetite, and sometimes diarrhea. Because these symptoms overlap with many common feline illnesses, the disease often flies under the radar for months before a diagnosis is made.

Cattle and Bovine Leukemia Virus

In cattle, lymphosarcoma is most commonly tied to bovine leukemia virus (BLV), which causes a condition called enzootic bovine leukosis. BLV is considered the most prevalent neoplastic disease in cattle worldwide.

⁴

The infection spreads through blood contact, contaminated needles, or biting insects, and it is remarkably widespread in dairy herds in many countries. However, the path from infection to cancer is far from inevitable. Research estimates that only about 1.4 percent of BLV-infected cattle actually develop clinical lymphosarcoma, and the incubation period is long, often years.

⁵

When a cow does develop lymphosarcoma, it usually appears as enlarged lymph nodes, masses in the heart, abomasum (one of the stomach compartments), uterus, or behind the eyes. The economic impact comes less from the small number of clinical cases and more from trade restrictions, reduced milk production in subclinically infected cows, and carcass condemnations at slaughter.

How Lymphosarcoma Is Diagnosed

The quickest route to a diagnosis is often a fine needle aspirate, where a veterinarian inserts a thin needle into a swollen lymph node and pulls out cells for examination under a microscope. This is a fast, minimally invasive procedure that can be done in a regular exam room. In dogs, fine needle aspirate cytology is a standard first step because most lymphomas consist of large, easily recognizable abnormal lymphocytes.

⁶

Fine needle aspirates do have limits. A study evaluating lymph nodes of unknown cause found that cytology alone correctly diagnosed about half of cases, but when supported by additional immunotyping techniques, the success rate climbed substantially. Core needle biopsy, which extracts a small column of tissue, gave a reliable diagnosis in about 95 percent of cases.

⁷

For cattle with enlarged lymph nodes, both methods can aid diagnosis, and fine needle aspirate results were actually more specific and more predictive for a positive result than core needle biopsy in one comparative study.

⁸

Immunophenotyping and Why It Matters

Once lymphoma is confirmed, knowing whether it is made up of B cells or T cells changes the prognosis and sometimes the treatment plan. B-cell lymphoma is more common in dogs and tends to respond better to chemotherapy. T-cell lymphoma generally carries a worse outlook. Figuring out which type you’re dealing with requires specialized testing beyond what a basic microscope slide can offer.

Flow cytometry, which analyzes the surface markers on individual cells in a liquid sample, has proven to be the most accurate tool for this job. In a study comparing flow cytometry, immunohistochemistry, and a DNA-based technique called PARR, flow cytometry correctly identified B-cell lymphoma in about 91 percent of cases and T-cell lymphoma in 100 percent. PARR, which looks for clonal rearrangements of antigen receptor genes, was less sensitive but still useful when fresh tissue was not available for flow cytometry.

⁹

Staging the Disease

Staging determines how far the cancer has spread, which shapes decisions about treatment intensity. In dogs with multicentric lymphoma, the staging system runs from I to V. Stage I means a single lymph node is affected. Stage II involves multiple nodes in one region. Stage III means generalized lymph node enlargement. Stage IV adds involvement of the liver or spleen, and stage V indicates bone marrow or blood involvement or disease in non-lymphoid organs. Each stage is further divided into substage “a” (the dog feels well) or substage “b” (the dog is showing clinical signs like fever, weight loss, or lethargy).

¹⁰

That substage distinction is important. Dogs classified as substage “b” consistently have shorter survival times than substage “a” dogs, even within the same stage. A dog at stage IV-a that still eats well and plays normally often does better than a stage III-b dog that has already lost weight and energy. This is one reason veterinary oncologists push to start treatment before the disease visibly takes a toll.

Chemotherapy as the Standard Treatment

For dogs with multicentric lymphoma, multi-drug chemotherapy is the backbone of treatment. The most widely used approach is a CHOP-based protocol, adapted from human oncology. It typically combines cyclophosphamide, a vinca alkaloid like vincristine, an anthracycline like doxorubicin, and a corticosteroid like prednisone, sometimes with L-asparaginase added early on. A large review encompassing over 4,300 dogs treated with CHOP-like protocols confirmed this as the standard approach for generalized nodal lymphoma.

¹¹

Most dogs respond well initially. Remission rates above 80 percent are common with CHOP protocols, and many dogs regain a normal quality of life quickly. The challenge is that remission is usually temporary. In one study of 130 dogs treated with a dose-intensified CHOP protocol, the median time to disease progression was 219 days (about seven months) and median lymphoma-specific survival was 323 days (roughly eleven months). Interestingly, dogs that needed dose reductions because of side effects actually lived longer, suggesting that finding the right balance of intensity for each individual matters more than pushing doses to the maximum.

¹²

Adding mitoxantrone as a maintenance agent after the initial CHOP induction has shown promise. One protocol combining CHOP induction with mitoxantrone maintenance achieved a median remission of 302 days and a median overall survival of 622 days, roughly 20 months.

¹³

For owners who cannot pursue multi-drug chemotherapy because of cost or logistics, prednisone alone can provide a modest response. It shrinks lymph nodes and improves how the dog feels for a period, but survival on prednisone alone is measured in weeks to a few months rather than many months to over a year.

¹⁴

When Cancer Comes Back

Relapse is, unfortunately, the rule rather than the exception in canine lymphoma. When it happens, options narrow but do not disappear. A study of 265 dogs receiving their first rescue chemotherapy after relapse reported an overall median progression-free survival of 56 days. Among the factors that predicted better outcomes, the most significant was achieving a complete response to the rescue protocol. Dogs treated with a CHOP-like rescue protocol fared better than those on single-agent regimens, and inclusion of prednisone in the rescue plan was also beneficial.

¹⁵

A newer drug called rabacfosadine has carved out a role specifically for relapsed B-cell lymphoma in dogs. It works as a prodrug that preferentially targets cancerous lymphocytes while causing less collateral damage to other tissues. In one study of 50 dogs with relapsed B-cell lymphoma, the overall response rate was 74 percent, with 45 percent achieving a complete response and a median progression-free interval of about 108 days for all dogs and 203 days for those with complete responses.

¹⁶

Combining rabacfosadine with L-asparaginase has also been evaluated. In a study of 46 dogs with relapsed or refractory multicentric lymphoma, the combination produced a 67 percent overall response rate, with a median progression-free survival of 63 days for all dogs and 144 days for those who achieved a complete response.

¹⁷

Drug Resistance

One reason relapsed lymphoma becomes harder to treat is the development of drug resistance. A protein called P-glycoprotein, which acts as a molecular pump pushing drugs out of cancer cells, is a major player. In a landmark human lymphoma study, P-glycoprotein was detected in only about 2 percent of untreated lymphoma patients, but in 64 percent of previously treated, drug-resistant patients. The study also showed that adding verapamil, a calcium channel blocker that inhibits P-glycoprotein, could partially restore drug sensitivity and produce responses in carefully selected resistant cases.

¹⁸

This mechanism operates across species. Canine lymphoma cells that survive initial chemotherapy can upregulate the same efflux pumps, which is why second and third remissions tend to be shorter and harder to achieve than the first.

Radiation Therapy for Localized Disease

While chemotherapy dominates the treatment landscape for widespread lymphoma, radiation therapy earns a place when the disease is confined to one area. In a study of dogs with localized oral lymphoma treated with radiation, median survival was 770 days, well over two years, and the treatment was well tolerated.

¹⁹

Cats with nasal lymphoma, a relatively common and often localized presentation, also benefit from radiation. A study of 32 cats treated with stereotactic body radiation for nasal and nasopharyngeal lymphoma found the approach to be effective and well tolerated, with outcomes for lower-stage disease comparable to conventional fractionated radiation.

²⁰

Paraneoplastic Complications

Lymphosarcoma does not always limit its damage to the organs it physically invades. The cancer can trigger a range of body-wide problems called paraneoplastic syndromes. The most clinically significant of these is hypercalcemia, an abnormally high calcium level in the blood. This occurs most often with T-cell lymphoma and is driven by the tumor producing a protein called parathyroid hormone-related protein (PTHrP), which mimics the effect of parathyroid hormone and pulls calcium from bones into the bloodstream.

²¹

High blood calcium causes excessive thirst and urination, nausea, muscle weakness, and if left unchecked, kidney damage. In dogs, hypercalcemia can be the first clue that lymphoma is present before the lymph nodes are noticeably enlarged. Treating the underlying cancer usually resolves the calcium imbalance, but supportive measures like intravenous fluids and diuretics are often needed in the short term.

Environmental Risk Factors

The cause of lymphosarcoma in any given animal is almost never traced to a single factor, but research has identified a few environmental exposures that increase risk. A study using canine lymphoma as a model for human non-Hodgkin lymphoma found that professionally applied pesticides were associated with a 70 percent higher risk of lymphoma in dogs. Self-applied insect growth regulators carried an even higher risk, roughly 2.7 times the odds compared to unexposed dogs. Routine flea and tick products, however, were not linked to increased risk.

²²

These findings carry dual significance. For pet owners, they suggest that minimizing unnecessary chemical lawn treatments may be a reasonable precaution. For epidemiologists, they add to growing evidence that environmental chemical exposure contributes to lymphoma risk in mammals more broadly.

Dogs as Models for Human Lymphoma

Canine lymphosarcoma is not just a veterinary problem. It has become one of the most valuable comparative models for studying human non-Hodgkin lymphoma. The full spectrum of lymphoid cancers seen in people also occurs in dogs, and the tumors share not just their appearance under the microscope and clinical behavior but also many of the same molecular abnormalities driving them. Dogs develop lymphoma spontaneously, live with their owners in the same environments, and have disease courses that compress into months rather than years, making clinical trials faster and more feasible.

²³

This comparative work has practical payoffs going both directions. Drugs developed initially for human patients, like CHOP-based chemotherapy, crossed into veterinary practice and became the standard of care for canine lymphoma. Conversely, newer agents like rabacfosadine were first studied in dogs and could inform the development of similar therapies for people. The shared biology means that understanding what makes one species’ lymphoma resistant to treatment often sheds light on the same problem in the other.